

## Original Research Article

### **DISSEMINATION OF MULTIDRUG-RESISTANT, EXTENSIVELY DRUG RESISTANT AND PANDRUG-RESISTANT *Pseudomonas aeruginosa* ISOLATES AMONG IN-PATIENTS AND OUT-PATIENTS IN A MULTI-PROFILE HEALTH CARE SETTINGS.**

#### **Abstract**

*Pseudomonas aeruginosa* is one of the most life threatening pathogens, especially in healthcare settings and a main contributors to multi-drug resistance (MDR), extensive-drug resistance (XDR) and pan-drug resistant (PDR) phenotype. However, there is limited data on the degree of resistance of these isolates in this region. The aim of this study was to determine the distribution of MDR, XDR and PDR *Pseudomonas aeruginosa* strains from different patients group. A total of five hundred (500) non-duplicated strains of *Pseudomonas aeruginosa* of human clinical samples were collected from Microbiology Laboratory Unit of Alex Ekwueme teaching hospital Abakaliki. The isolates were identified and re-characterized by standard microbiology techniques. MDR, XDR and PDR was determined using the Kirby–Bauer disk diffusion method and the results were analysis using the Clinical Laboratory Standard Institute (CLSI) zone diameter breakpoints. The result shows that the overall resistant phenotypewereMDR 50.7 %, XDR 20.5 %, PDR 9.6 % while samples from in-patients and out-patients, resistant phenotype proportion was MDR 43.2 %, XDR 32.4 %, PDR 10.1 % and MDR 61.2 %, XDR 29.7 %, PDR 18.5 % respectively. Worryingly, only few tested antimicrobial agents (Amikacin, cefepime) were active against the test organism, presenting a limited therapeutic option. It is therefore imperative to establish strong regulative measures and guidelines that would help in curtailing the increasing dissemination of these superbugs in healthcare institutions in Nigeria.

**Keywords:** Multidrug-Resistant, Extensively Drug Resistant, Pandrug-Resistant, *Pseudomonas aeruginosa*

#### **1. INTRODUCTION**

*Pseudomonas aeruginosa* is one of the most important causes of community and healthcare-related opportunistic infections among Gram-negative bacteria[1]. *P. aeruginosa* infections are very difficult to eradicate due to their intrinsic resistance to antibiotics, in addition, to various virulence factors like flagellin and lipopolysaccharide, as well as secreted products such as cytotoxins, elastase, alkaline protease, protease IV, as well as its invasiveness and increased colonization has been reported to contribute to its pathogenicity [2]. *P. aeruginosa* is divided into different phenotypes based on the drug resistance patterns of the organism. Multidrug-resistant (MDR) phenotype is defined as *P. aeruginosa*, which is resistant to more than one antimicrobial agent in three or more antimicrobial categories. A similar resistance to more than one antimicrobial agent in <3 antimicrobial categories is defined as drug-resistant (DR) *P. aeruginosa*. Extensively DR (XDR) phenotype is defined as *P. aeruginosa*, which is resistant to more than one antimicrobial agent in all the antimicrobial categories, except in two or less. Pan-DR (PDR) phenotype is defined as a bacterium which is resistant to all antimicrobial agents in all

antimicrobial categories [3, 4]. Worldwide *Pseudomonas aeruginosa* is one of the most common life threatening pathogens, and a main contributors to multi-drug resistance (MDR), extensive-drug resistance (XDR) and pan-drug resistant (PDR) phenotype in hospital and community settings [5, 6, 7, 8, 9, 10]. MDR, XDR and PDR strain are capable of stalling the action of antimicrobial agent due to the production of enzyme such as extended-spectrum beta-lactamases (ESBL) and metallo-β-lactamases (MBL), that truncate the action of beta-lactams and carbapenems [1, 11, 12, 13]. The dissemination of MDR, XDR and PDR through patients' movement from community to hospital or either way may facilitate the spread and convergence of such resistance phenotype among inpatients and outpatient. With the ever-increasing level of indiscriminate use of antimicrobial agent and rapid dissemination of MDR, XDR and PDR strains in the tropical countries like ours, the best therapeutic approach has proved to be controversial, leaving few alternatives for treatment of these patients. The menace of MDR, XDR and PDR *Pseudomonas aeruginosa* is of physical, emotional and financial detriment to patients globally with increased morbidity and mortality. Therefore, the need to identify and ascertain the rate of MDR, XDR and PDR *Pseudomonas aeruginosa* in a multipurpose healthcare system is of public health importance.

## 2. METHODS

### 2.1 Study area and Ethical Consideration

This study was carried out at Alex Ekwueme Federal University Teaching Hospital Abakaliki, Ebonyi State. It is a multipurpose healthcare setting in Abakaliki town, the capital city of Ebonyi State and it's located at 6.3231°N latitude and 8.1121°E longitude. The ethical approval for the study was granted in 2022 by the AE-FUTHA Ethics and Research Committee with reference number: SMOH/ERC/043/22. Every fundamental study was done in accordance with the ARRIVE guidelines.

### 2.2 Bacteriological Analysis

A total of five hundred (500) non-duplicated *Pseudomonas aeruginosa* of human clinical samples were collected from microbiology laboratory unit among inpatients [250] and outpatients [250] attending Alex Ekwueme Federal University Teaching Hospital, Abakaliki (AE-FUTHA) during a period of 12 months. The isolates were further isolated on *Pseudomonas* Isolation Agar (PIA) (Merck Co., Germany) and incubated at 35 °C for 18–24 h. After incubation, *Pseudomonas aeruginosa* was identified by standard microbiology techniques such as colonial morphology, Gram staining, motility, and biochemical tests as previously described [1, 14].

### 2.3 Screening for Multidrug-Resistant, Extensively Drug Resistant and Pandrug-Resistant


This was done by disc diffusion technique on MHA according to the guidelines of Clinical and Laboratory Standards Institute [15]. The following antibiotics were tested against the test bacteria: ceftriaxone (30 µg), Aztreonam (30 µg), cefotaxime (30 µg), tetracycline (30 µg), ceftazidime (30 µg), cefepime (10 µg), aztreonam (30 µg), amoxicillin clavulanic acid (20/10 µg), Piperacillin/tazobactam (30 µg), trimethoprim-sulphamethoxazole (125/23.75 µg), nalidixic acid (30 µg), colistin (10 µg) and amikacin (30 µg) (Oxoid, UK). Zones of inhibition diameters were measured, recorded, and interpreted as resistant or susceptible according to established guidelines [13, 15]. Multidrug-resistant organisms (MDR) are described as acquired non-sensitivity to one or more agents in at least three groups of antimicrobials [14]. XDR = non-susceptible to ≥1 agent in all but ≤2 categories and Pan-Drug = non-susceptible to all antimicrobial agents listed [3, 16].

## 3. RESULT AND DISCUSSION


### 3.1 Result

The result shows that the overall resistant phenotype were MDR 50.7 %, XDR 20.5 %, PDR 9.6 % (Figure 1) while samples from in-patients and out-patients, resistant phenotype proportion was MDR

43.2 %, XDR 32.4 %, PDR 10.1 % and MDR 61.2 %, XDR 29.7 %, PDR 18.5 % respectively as presented in Figure 2.



**Figure 1: Chart showing the proportion of MDR, XDR and PDR among patients group**



### 3.2 Discussion

*Pseudomonas aeruginosa* in both samples of in-patients and out-patients in multipurpose healthcare institutions had occurrence frequencies as high as 43.2–61.2%. Our finding agrees with report from other studies [17, 18, 19]. Improper antibiotic prescriptions in our hospital could be a possible reason for this resistant features. Additionally, MDR-*P. aeruginosa* has been considered a serious threat by the Centers for Disease Control and Prevention (CDC) for the last decade, accounting for at least 32,600 cases, 2700 deaths, and US \$767 million in attributable healthcare costs annually [1, 2, 20]. As stated in several studies, septicemia or pneumonia caused by MDR-*P. aeruginosa* isolates resulted in poor patient outcomes [21, 22, 23, 24, 25]. Recommendations for the treatment of MDR *P. aeruginosa* infections have been published based on the susceptibility profiles of conventional and novel antibiotics [17, 26, 27]. Clearly, antibiotic combination therapy is likely to select mutants displaying a broader resistance phenotype (e.g., mutational inactivation of the repressor gene *mexR* that regulates the multidrug efflux operon *mexAB–oprM* for *P. aeruginosa*) than before [28]. Furthermore, the proportion of patients who received delayed appropriate therapy increased as the number of resistant classes increased. Specifically, antibiotic resistance to at least three antibiotic classes was significantly associated with delayed appropriate therapy [29].

In this study, 29.7 % and 32.4 % XDR were found in the isolate. The observed phenotype has been reported in Greece, Pakistan, Canada and elsewhere [5, 30, 31, 32]. In a US national database study, patients with *P. aeruginosa* respiratory infections had higher mortality, approximately 7 days longer hospital length of stay (LOS), higher readmission rates, Multidrug-resistant (MDR) and extensively drug-resistant (XDR) *Pseudomonas aeruginosa* represents a frequent and challenging nosocomial pathogen with consistently high rates that range from 11.5% to 24.7% and 9.0% to 11.2%, respectively, according to the INFORM database [33]. The World Health Organization (WHO) designated *P. aeruginosa* a priority 1 or “critical” pathogen in substantial need of new therapies to counteract this imminent public health crisis of resistance [29]

Resistant to all anti-pseudomonal drugs (PDR) had a proportion of 10.1 % and 18.5 % respectively. Infections caused by PDR *P. aeruginosa* strains could be associated with high morbidity and mortality

rates, as well as increased durations of hospital stays and overall costs of treatment. *Pseudomonas aeruginosa* has an extraordinary capacity to confer resistance via multiple mechanisms, often at the same time, resulting in resistance to nearly all available antibiotics. Major *P. aeruginosa* resistance mechanisms are often classified into intrinsic and acquired, which counter most antibiotics, as well as adaptive, which includes biofilm-mediated resistance and the formation of multidrug-tolerant persister cells [10, 12, 29, 34]. In Nigeria, beta-lactams, cephalosporins, aminoglycosides, fluoroquinolones, tetracyclines, and folate pathway inhibitors are widely used in treating arrays of bacterial infections (such as UTIs, pneumonia, enteritis, and septicemia) and may likely result in selective pressure, thus favoring the evolution and development of MDR, XDR and PDR bacterial pathogens which suppresses the normal commensal bacteria.

*P. aeruginosa* high level of intrinsic resistance occurs through restricted outer membrane permeability (approximately 12–100-fold lower than that of *Escherichia coli*), presence of antibiotic efflux systems, and the production of endogenous antibiotic-inactivating enzymes [29, 34]. Acquired resistance mechanisms result from either horizontal gene transfer (acquisition of aminoglycoside-modifying enzymes and  $\beta$ -lactamases) or mutational events that result in the overexpression of efflux pumps or  $\beta$ -lactamases or the decreased expression or modification of target sites and porins [29, 34]. Adaptive resistance mechanisms are induced by external stimuli (e.g., antibiotic exposure) and become inactive upon removal of the stimulus [29, 34]. This resistant mechanism are the mainstay of progressive dissemination of MDR, XDR and PDR among patients and may spread to another bacteria strain. It should be noted that, improper antimicrobial use, improper dose, and duration of administration as predisposing factors contributing to the emergence of MDR, XDR and PDR strains in a locality.

#### 4. CONCLUSION

This present study reports the dissemination of MDR, XDR and PDR among in patients. Worryingly, only few tested antimicrobial agent (Amikacin, cefepime) were susceptible, presenting a limited therapeutic option. The alarming high frequency of MDR, XDR and PDR traits reported in this study poses significant concerns for treatment failures and emphasizes the urgent need for regulatory measures to curtail their dissemination and reduce their disease burden in healthcare settings. Proper medical guidance and avoidance of misuse of these antimicrobials agent in our study area should be adopted.

#### REFERENCES

1. Ogba, R. C., Nomeh, O. L, Edemekong, C. I., Nwuzo, A. C., Akpu, P. O., **Peter, I. U** and Iroha, I. R (2022a). Molecular Characterization of Carbapenemase Encoding Genes in *Pseudomonas aeruginosa* from Tertiary Healthcare in South Eastern Nigeria. *Asian Journal of Biology, Genetic and Molecular Biology*, **12**(4):161-168.
2. Rodulfo, H., Arcia, A., Hernández, A., Michelli, E., Martinez, D. D. V., Guzman, M., Sharma, A and Donato, M (2019). Virulence factors and integrons are associated with MDR and XDR phenotypes in nosocomial strains of *Pseudomonas aeruginosa* in a Venezuelan university hospital. *Review in Institute of Medical Tropicalis Sao Paulo*, **61**:20-23.
3. Gill, C. M., Aktap, E., Alfouzan, W., Bourassa, L., Brink, A., Burnham, C. D., Canton, R., Carmeli, Y., Falcone, M., Kiffer, C., Marchese, A., Martinez, O., Pournaras, S., Satlin, M., Seifert, H., Thabit, A. K., Thomson, K. S., Villegas, M. V., Nicolau, D. P and ERACE-PA Global Study Group (2021). The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant

- Pseudomonas aeruginosa*. *European Journal of Clinical Microbiology Infectious Disease*, **40**(12):2533–2541.
4. Tenover, F. C., Nicolau, D P and Gill, C. M (2022) Carbapenemase producing *Pseudomonas aeruginosa* –an Emerging Challenge. *Emerging Microbes and Infections*, **11**:1811-814
  5. Saleem, S and Bokhari, H (2019). Resistance Profile of Genetically Distinct Clinical *Pseudomonas aeruginosa* Isolates from Public Hospitals in Central Pakistan. *Journal of Infection and Public Health*, **13**(4):598–605.
  6. Mirzaei, B., Bazgir, Z. N., Goli, H. R., Iranpour, F., Mohammadi, F and Babaei, R (2020). Prevalence of Multi-drug Resistant (MDR) and Extensively Drug-resistant (XDR) Phenotypes of *Pseudomonas aeruginosa* and *Acinetobacter baumannii* Isolated in Clinical Samples from Northeast of Iran. *BMC Research Notes*, **13**:380-400.
  7. Uzoiye U N, Moses I B, Nwakaeze E A, Uzoeto H O, Otu J O, Egbuna N R, Ngwu J N, Chukwunwejim C R, Mohammed D I, Peter I U, Oke B, Iroha I R. Prevalence of Multidrug-resistant Bacteria Isolates in Waste Water from Different Hospital Environment in Umuahia, Nigeria. *Int. J. Pharm. Sci. Rev. Res.* 2021; **69**(2): 25-32.
  8. Udu-Ibiam O E, Chukwu S K, Peter I U, Nwankwo C E, Iganga, N, Akindele K I. Antibiotic susceptibility pattern of bacteria isolated from freshly cut watermelon fruit sold within Abakaliki metropolis (Presco junction) Ebonyi State Nigeria. *IDOSR J Experimental Sciences*; 2021; **6**(1) 127-132, 2021.
  9. Liu, G and Qin, M (2022). Analysis of the Distribution and Antibiotic Resistance of Pathogens Causing Infections in Hospitals from 2017 to 2019. *Evidence-Based Complementary and Alternative Medicine*, **17**:20-23.
  10. Hafiz, T.A., Bin Essa, E.A., Alharbi, S.R., Alyami, A.S., Alkudmani, Z.S., Mubarak, M.A., Alturki, N.A and Alotaibi, F (2023). Epidemiological, Microbiological, and Clinical Characteristics of Multi-Resistant *Pseudomonas aeruginosa* Isolates in King Fahad Medical City, Riyadh, Saudi Arabia. *Journal of Tropical Medicine and Infectious Disease*, **8**:205-207.
  11. Oke B, Iroha I R, Moses I B , Egwu I H, Elom E, Uzoh C V, Nwode V F, Okpada J O, Agbom J N, Peter I U, Ibeka G U. Killing Rate Kinetics of Commercially Available Brands of Ciprofloxacin and Cefotaxime on Clinical Bacterial Isolates Subjected to *in vitro* Antibiotic Treatments. *Int. J. Pharm. Sci. Rev. Res.* 2020; **64**(2):87-97
  12. Ogba RC, Akpu PO, Nwuzo AC, Peter IU, Nomeh OL, Iroha IR (2022b). Antibiotic Susceptibility Profile of clinical isolate of carbapenem-resistant *Pseudomonas aeruginosa*. *South Asian J Res Microbiol.* 2022; **14** (2):14-23.
  13. Joseph I S, Okolo I O, Udenweze E C, Nwankwo C E, Peter I U, Ogonna I P, Iroha I R. Comparison of Antibiotic-Resistant Pattern of Extended Spectrum Beta-Lactamase and Carbapenem- Resistant *Escherichia Coli* Isolates from Clinical and Non-Clinical Sources. *J Drug Delivery and Therapeutics.* 2023; **13**(7):107-118
  14. Edemekong, CI, Iroha IR, Thompson, MD, Okolo, IO., Uzoeto HO, Ngwu JN, Mohammed ID, Chukwu EB, Nwuzo AC, Okike BM, Okolie SO, Peter IU. Phenotypic characterization and antibiogram of non-oral bacteria isolates from patients attending dental clinic at Federal College of Dental Technology and Therapy Medical Center Enugu. *Int J Pathog Res.* 2022; **11**(2):7-19.
  15. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; twenty-eighth edition (M100). Wayne, PA: Clinical and Laboratory Standards Institute; 2019.
  16. Rodulfo, H., Arcia, A., Hernández, A., Michelli, E., Martinez, D. D. V., Guzman, M., Sharma, A and Donato, M (2019). Virulence factors and integrons are associated with MDR and XDR phenotypes in nosocomial strains of *Pseudomonas aeruginosa* in a Venezuelan university hospital. *Review in Institute of Medical Tropicalis Sao Paulo*, **61**:20-23.
  17. Bassetti, M., Echols, R., Matsunaga, Y., Ariyasu, M., Doi, Y and Ferrer, R (2021). Efficacy and Safety of Cefiderocol or Best Available Therapy for the Treatment of Serious Infections Caused by

- Carbapenem-Resistant Gram- Negative Bacteria (CREDIBLE-CR): A Randomised, Open-Label, Multicentre, Pathogen-Focused, Descriptive, Phase 3 Trial. *Lancet of Infectious Disease*, **21**:226–240.
18. Siriyong, T., Murray, R. M., Bidgood, L. E., Young, S. A., Wright, F and Parcell, B. J (2019). Dual beta-Lactam Combination Therapy for Multi-Drug Resistant *Pseudomonas aeruginosa* Infection: Enhanced Efficacy *In Vivo* and Comparison With Monotherapies of Penicillin-Binding Protein Inhibition. *Scientific Report*, **9**:90-98.
  19. Olsson, A., Wistrand-Yuen, P., Nielsen, E. I., Friberg, L. E., Sandegren, L and Lagerbäck, P (2020). Efficacy of Antibiotic Combinations against Multidrug-Resistant *Pseudomonas aeruginosa* in Automated Time-Lapse Microscopy and Static Time-Kill Experiments. *Journal of Antimicrobial Agent and Chemotherapy*, **64**:2111-19.
  20. Tada, T., Hishinuma, T., Watanabe, S., Uchida, H., Tohya, M and Kuwahara-Arai, K (2019). Molecular Characterization of Multidrug-resistant *Pseudomonas aeruginosa* Isolates in hospitals in Myanmar. *Journal of Antimicrobial Agent and Chemotherapy*, **63**:34-78.
  21. Hirsch, E. B and Tam, V. H (2010b). Impact of Multidrug-Resistant *Pseudomonas aeruginosa* Infection on Patient Outcomes. *Expert Review in Pharmacoeconomic Outcomes Research*, **10**:441–451.
  22. Morata, L., Cobos-Trigueros, N., Martínez, J. A., Soriano, A., Almela, M and Marco, F (2012). Influence of Multidrug Resistance and Appropriate Empirical Therapy on the 30-Day Mortality Rate of *Pseudomonas aeruginosa* Bacteremia. *Journal of Antimicrobial Agents and Chemotherapy*, **56**:4833–4837
  23. Micek, S. T., Wunderink, R. G., Kollef, M. H., Chen, C., Rello, J and Chastre, J (2015). An International Multicenter Retrospective Study of *Pseudomonas aeruginosa* Nosocomial Pneumonia: Impact of Multidrug Resistance. *Critical Care*, **19**:219-221.
  24. Matos, E. C., Andriolo, R. B., Rodrigues, Y. C., Lima, P. D., Carneiro, I. C and Lima, K.V (2018). Mortality in Patients with Multidrug-resistant *Pseudomonas aeruginosa* Infections: A Meta-analysis. *Review of Society of Brasillian Medicine Tropic*, **51**(4):415–20.
  25. Urzedo, J. E., de Paula Menezes, R., Porto, J. P., Ferreira, M. L., Gonçalves, I. R and de Brito, C. S (2020). High Mortality by Nosocomial Infections Caused by Carbapenem-Resistant *P. aeruginosa* in a Referral Hospital in Brazil: Facing the Perfect Storm. *Journal of Medical Microbiology*, **69**:1388–1397.
  26. Jean, S. S., Gould, I. M., Lee, W. S and Hsueh, P. R (2019). New Drugs for Multidrug-Resistant Gram-Negative Organisms: Time for Stewardship. *Drugs*, **79**:705–714.
  27. Jean, S. S., Lee, Y. L., Liu, P. Y., Lu, M. C., Ko, W. C and Hsueh, P. R (2021). Multicenter Surveillance of Antimicrobial Susceptibilities and Resistance Mechanisms among Enterobacterales Species and non-Fermenting Gram- Negative Bacteria from Different Infection Sources in Taiwan From 2016 to 2018. *Journal of Microbiology and Immunology of Infection*, **1684**(21):182-1.
  28. Vestergaard, M., Paulander, W., Marvig, R. L., Clasen, J., Jochumsen, N and Molin, S (2016). Antibiotic Combination Therapy can Select for Broad-Spectrum Multidrug Resistance in *Pseudomonas aeruginosa*. *International Journal of Antimicrobial Agent*, **47**:48–55.
  29. Kunz Coyne, A. J., Amer, E., Dana, H., Nicholas, R and Michael, J R (2022). Therapeutic Strategies for Emerging Multidrug- Resistant *Pseudomonas aeruginosa*. *Infectious Disease Therapy*, **11**:661–682.
  30. Bhagwat, S. S., Legakis, N. J., Skalidis, T., Loannidis, A., Goumenopoulos, C., Joshi, P. R., Shrivastava, R., Palwe, S. R., Periasamy, H and Patel, M.V (2021). *In vitro* Activity of Cefepime/zidebactam (WCK 5222) against recent Gram-negative Isolates Collected from High Resistance Settings of Greek Hospitals. *Diagnostic Microbiological Infectious Disease*, **100**:115-327
  31. McCracken, M. G., Adam, H. J., Blondeau, J. M., Walkty, A. J., Karlowsky, J. A and Hoban, D. J (2019). Characterization of Carbapenem-Resistant and XDR *Pseudomonas aeruginosa* in Canada:

- Results of the CANWARD 2007-16 Study. *Journal of Antimicrobial Agent and Chemotherapy*, **74**:32–38
32. Pérez, A., Gato, E., Pérez-Llarena, J., Fernández-Cuenca, F., Gude, M. J., Oviaño, M., Pachón, M. E., Garnacho, J., González, V and Pascual, Á (2019). High Incidence of MDR and XDR *Pseudomonas aeruginosa* Isolates Obtained from Patients with Ventilator-associated pneumonia in Greece, Italy and Spain as part of the Magic Bullet Clinical Trial. *Journal of Antimicrobial Agent and Chemotherapy*, **74**(5):1244–52.
  33. Sader, H. S., Carvalhaes, C. G., Arends, S. J. R., Castanheira, M and Mendes, R. E (2021). Aztreonam/avibactam Activity against Clinical Isolates of Enterobacterales Collected in Europe, Asia and Latin America in 2019. *Journal of Antimicrobial Agent and Chemotherapy*, **76**:659–666.
  34. Losito, A. R., Raffaelli, F., Del Giacomo, P and Tumbarello, M (2022). New Drugs for the Treatment of *Pseudomonas aeruginosa* Infections with Limited Treatment Options: A Narrative Review. *Antibiotics*, **11**:579-578.

UNDER PEER REVIEW